tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
View Detailed Chart

2.880USD

+0.070+2.49%
Close 09/18, 16:00ETQuotes delayed by 15 min
416.49MMarket Cap
LossP/E TTM

Maravai LifeSciences Holdings Inc

2.880

+0.070+2.49%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.49%

5 Days

+3.23%

1 Month

+12.06%

6 Months

+11.63%

Year to Date

-47.16%

1 Year

-68.56%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
59 / 506
Overall Ranking
152 / 4721
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 12 analysts
Buy
Current Rating
4.125
Target Price
+46.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Fairly Valued
The company’s latest PE is -2.10, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 144.27M shares, decreasing 15.17% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.38M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Ticker SymbolMRVI
CompanyMaravai LifeSciences Holdings Inc
CEOMr. Bernd Brust
Websitehttps://www.maravai.com/
KeyAI